Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emyr Bakker

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Future Oncology (London, England)|August 29, 2020
The use of multi-omics data and approaches in breast cancer immunotherapy: a reviewKa Lun Leung, Devika Verma, Younus Jamal Azam, et al.
Biochimica Et Biophysica Acta|August 10, 2015
The role of microenvironment and immunity in drug response in leukemiaEmyr Bakker, Malak Qattan, Luciano Mutti, et al.
Expert Review of Anticancer Therapy|July 21, 2017
Immunotherapy advances for mesothelioma treatmentEmyr Bakker, Alice Guazzelli, Firozeh Ashtiani, et al.
Expert Opinion on Investigational Drugs|July 7, 2017
Promising investigational drug candidates in phase I and phase II clinical trials for mesotheliomaAlice Guazzelli, Emyr Bakker, Kun Tian, et al.
Plos Computational Biology|November 7, 2017
Insight into glucocorticoid receptor signalling through interactome model analysisEmyr Bakker, Kun Tian, Luciano Mutti, et al.
Immunotherapy|February 25, 2017
Anti-CTLA-4 therapy for malignant mesotheliomaAlice Guazzelli, Emyr Bakker, Marija Krstic-Demonacos, et al.
International Journal of Molecular Sciences|January 24, 2019
<i>BAP1</i> Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine TreatmentAlice Guazzelli, Parisa Meysami, Emyr Bakker, et al.
Expert Opinion on Investigational Drugs|July 3, 2019
What can independent research for mesothelioma achieve to treat this orphan disease?Alice Guazzelli, Parisa Meysami, Emyr Bakker, et al.
Journal of Translational Medicine|October 15, 2018
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identificationKun Tian, Emyr Bakker, Michelle Hussain, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Future Oncology (London, England)|August 29, 2020
The use of multi-omics data and approaches in breast cancer immunotherapy: a reviewKa Lun Leung, Devika Verma, Younus Jamal Azam, et al.
Biochimica Et Biophysica Acta|August 10, 2015
The role of microenvironment and immunity in drug response in leukemiaEmyr Bakker, Malak Qattan, Luciano Mutti, et al.
Expert Review of Anticancer Therapy|July 21, 2017
Immunotherapy advances for mesothelioma treatmentEmyr Bakker, Alice Guazzelli, Firozeh Ashtiani, et al.
Expert Opinion on Investigational Drugs|July 7, 2017
Promising investigational drug candidates in phase I and phase II clinical trials for mesotheliomaAlice Guazzelli, Emyr Bakker, Kun Tian, et al.
Plos Computational Biology|November 7, 2017
Insight into glucocorticoid receptor signalling through interactome model analysisEmyr Bakker, Kun Tian, Luciano Mutti, et al.
Immunotherapy|February 25, 2017
Anti-CTLA-4 therapy for malignant mesotheliomaAlice Guazzelli, Emyr Bakker, Marija Krstic-Demonacos, et al.
International Journal of Molecular Sciences|January 24, 2019
<i>BAP1</i> Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine TreatmentAlice Guazzelli, Parisa Meysami, Emyr Bakker, et al.
Expert Opinion on Investigational Drugs|July 3, 2019
What can independent research for mesothelioma achieve to treat this orphan disease?Alice Guazzelli, Parisa Meysami, Emyr Bakker, et al.
Journal of Translational Medicine|October 15, 2018
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identificationKun Tian, Emyr Bakker, Michelle Hussain, et al.
Pageof 1